AU2007204757B2 - Lanthionine-related compounds for the treatment of inflammatory diseases - Google Patents

Lanthionine-related compounds for the treatment of inflammatory diseases Download PDF

Info

Publication number
AU2007204757B2
AU2007204757B2 AU2007204757A AU2007204757A AU2007204757B2 AU 2007204757 B2 AU2007204757 B2 AU 2007204757B2 AU 2007204757 A AU2007204757 A AU 2007204757A AU 2007204757 A AU2007204757 A AU 2007204757A AU 2007204757 B2 AU2007204757 B2 AU 2007204757B2
Authority
AU
Australia
Prior art keywords
cio
heteroatom
compound
cell
lanthionine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007204757A
Other languages
English (en)
Other versions
AU2007204757A1 (en
Inventor
Kenneth Hensley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
Original Assignee
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Medical Research Foundation filed Critical Oklahoma Medical Research Foundation
Publication of AU2007204757A1 publication Critical patent/AU2007204757A1/en
Application granted granted Critical
Publication of AU2007204757B2 publication Critical patent/AU2007204757B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2007204757A 2006-01-09 2007-01-09 Lanthionine-related compounds for the treatment of inflammatory diseases Ceased AU2007204757B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US75725206P 2006-01-09 2006-01-09
US60/757,252 2006-01-09
US78179406P 2006-03-13 2006-03-13
US60/781,794 2006-03-13
US80414906P 2006-06-07 2006-06-07
US60/804,149 2006-06-07
PCT/US2007/060277 WO2007082208A2 (en) 2006-01-09 2007-01-09 Lanthionine-related compounds for the treatment of inflammatory diseases

Publications (2)

Publication Number Publication Date
AU2007204757A1 AU2007204757A1 (en) 2007-07-19
AU2007204757B2 true AU2007204757B2 (en) 2012-09-06

Family

ID=38051848

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007204757A Ceased AU2007204757B2 (en) 2006-01-09 2007-01-09 Lanthionine-related compounds for the treatment of inflammatory diseases

Country Status (10)

Country Link
US (1) US7683055B2 (cg-RX-API-DMAC10.html)
EP (1) EP1981862B1 (cg-RX-API-DMAC10.html)
JP (1) JP5367377B2 (cg-RX-API-DMAC10.html)
AT (1) ATE500236T1 (cg-RX-API-DMAC10.html)
AU (1) AU2007204757B2 (cg-RX-API-DMAC10.html)
CA (1) CA2636042C (cg-RX-API-DMAC10.html)
DE (1) DE602007012833D1 (cg-RX-API-DMAC10.html)
DK (1) DK1981862T3 (cg-RX-API-DMAC10.html)
PT (1) PT1981862E (cg-RX-API-DMAC10.html)
WO (1) WO2007082208A2 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2305834A1 (en) * 2009-10-02 2011-04-06 Advanced Practical Diagnostics N.V. Haplotype of KATIII gene
SG181983A1 (en) * 2009-12-28 2012-08-30 Ajinomoto Kk Lanthionine derivative
WO2011140215A2 (en) * 2010-05-04 2011-11-10 Virginia Tech Intellectual Properties, Inc. Lanthionine synthetase component c-like proteins as molecular targets for preventing and treating diseases and disorders
US20130209366A1 (en) * 2010-08-24 2013-08-15 Oklahoma Medical Research Foundation Glutathione-Lanthionine Compounds and Methods Related Thereto
CN102670796A (zh) * 2012-05-22 2012-09-19 广西天天乐药业股份有限公司 一种治疗脾胃虚弱的中药及其制备方法
JP2017141497A (ja) * 2016-02-12 2017-08-17 二村　芳弘 エラスチン増加作用を呈するメチルランチオニン誘導体の製造方法
US11084836B2 (en) * 2016-02-26 2021-08-10 The University Of Toledo Compositions useful in therapy of autophagy-related pathologies, and methods of making and using the same
WO2018156429A1 (en) * 2017-02-23 2018-08-30 The University Of Toledo Compositions useful in therapy of autophagy-related pathologies, and methods of making and using the same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166554A1 (en) * 2001-01-16 2003-09-04 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2283186A (en) * 1942-05-19 Thiazane-j
US6025395A (en) 1994-04-15 2000-02-15 Duke University Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders
US20030185754A1 (en) 2001-01-16 2003-10-02 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
CA2433866A1 (en) * 2001-01-16 2002-08-29 Genset S.A. Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166554A1 (en) * 2001-01-16 2003-09-04 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Eremeev, A.V., et al., Khimiya Geterotsiklicheskikh Soedinenii, 1983, vol. 10, pages 1357-1358 *
Hermann, P. Chemische Berichte, 1961, vol. 94, pages 442-445 *
Paradisi, M.P., et al., Journal of Heterocyclic Chemistry, 1990, vol. 27, no. 6, pages 1661-1664 *

Also Published As

Publication number Publication date
CA2636042A1 (en) 2007-07-19
ATE500236T1 (de) 2011-03-15
EP1981862B1 (en) 2011-03-02
JP5367377B2 (ja) 2013-12-11
CA2636042C (en) 2014-10-14
PT1981862E (pt) 2011-06-01
WO2007082208A3 (en) 2007-09-13
US20070197515A1 (en) 2007-08-23
WO2007082208A2 (en) 2007-07-19
AU2007204757A1 (en) 2007-07-19
US7683055B2 (en) 2010-03-23
EP1981862A2 (en) 2008-10-22
DE602007012833D1 (de) 2011-04-14
DK1981862T3 (da) 2011-06-14
JP2009522377A (ja) 2009-06-11

Similar Documents

Publication Publication Date Title
EP1981862B1 (en) Lanthionine-related compounds for the treatment of inflammatory diseases
KR101909433B1 (ko) 키나제 저해제의 부작용 저감제
JP2012131829A (ja) そう痒状態の処置のためのｍｇｌｕｒ５アンタゴニストの使用
JP2009535410A (ja) ピロロキノリンキノンおよびその使用
CN101151034A (zh) 含有前列腺素F2α衍生物作为有效成分的视网膜神经细胞保护剂
GB2345058A (en) Hydroxypyridone compounds useful in the treatment of oxidative damage to the central nervous system
JP2025163212A (ja) ｄ－アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス
JP6377620B2 (ja) グルコース取り込みを改善するための組成物および方法
CN112204025B (zh) 用于治疗疼痛的化合物，包含其的组合物以及使用其的方法
US20110224269A1 (en) Analgesic Compounds, Compositions, and Uses Thereof
US6943185B2 (en) Use of 2-methyl-thiazolidine-2,4-dicarboxylic acid and/or physiologically compatible salts thereof for producing a medicament for treating cancers
JP2012031173A (ja) メトキシポリエチレングリコールチオエステルキレートおよびその使用
US20100087398A1 (en) Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions
US20130209366A1 (en) Glutathione-Lanthionine Compounds and Methods Related Thereto
JP2002540150A (ja) ウイルス治療
US10829441B2 (en) Reactive oxygen species-sensitive nitric oxide synthase inhibitors for the treatment of ischemic stroke
WO2006014507A2 (en) Method for inhibiting lipid peroxidation

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired